ATE334216T1 - Impstoff gegen felines immunodefizienz-virus - Google Patents

Impstoff gegen felines immunodefizienz-virus

Info

Publication number
ATE334216T1
ATE334216T1 AT95915480T AT95915480T ATE334216T1 AT E334216 T1 ATE334216 T1 AT E334216T1 AT 95915480 T AT95915480 T AT 95915480T AT 95915480 T AT95915480 T AT 95915480T AT E334216 T1 ATE334216 T1 AT E334216T1
Authority
AT
Austria
Prior art keywords
gag
mucosal
parenteral
fiv
env
Prior art date
Application number
AT95915480T
Other languages
English (en)
Inventor
Richard C Wardley
David E Lowery
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE334216T1 publication Critical patent/ATE334216T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95915480T 1994-04-29 1995-04-05 Impstoff gegen felines immunodefizienz-virus ATE334216T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23642994A 1994-04-29 1994-04-29

Publications (1)

Publication Number Publication Date
ATE334216T1 true ATE334216T1 (de) 2006-08-15

Family

ID=22889471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95915480T ATE334216T1 (de) 1994-04-29 1995-04-05 Impstoff gegen felines immunodefizienz-virus

Country Status (8)

Country Link
US (1) US5833993A (de)
EP (2) EP1679377A1 (de)
JP (1) JPH09512177A (de)
AT (1) ATE334216T1 (de)
AU (1) AU2234995A (de)
DE (1) DE69535125T2 (de)
ES (1) ES2267101T3 (de)
WO (1) WO1995030019A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348449B1 (en) 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
US5849303A (en) * 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
US6254872B1 (en) * 1995-08-25 2001-07-03 University Of Florida Multi-subtype FIV vaccines
FR2741806B1 (fr) * 1995-11-30 1998-02-20 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
EP1860192A1 (de) * 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
US7255862B1 (en) 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
US20030118601A1 (en) * 1997-03-11 2003-06-26 Neil James Charles FIV vaccine
US6458528B1 (en) * 1998-05-15 2002-10-01 Idexx Laboratories, Inc. Diagnosis of feline immunodeficiency virus infection using ENV/GAG polypeptide markers
US6770282B1 (en) 1998-10-23 2004-08-03 Heska Corporation Cationic lipid-mediated enhancement of nucleic acid immunization of cats
AU1131200A (en) * 1998-10-23 2000-05-15 Heska Corporation Cationic lipid-mediated enhancement of nucleic acid immunization of cats
US20030198661A1 (en) * 2000-01-31 2003-10-23 Mars Incorporated Antioxidant compositions and methods for companion animals
EP1074625A3 (de) * 1999-06-14 2002-01-02 Pfizer Products Inc. DNS impfstoff gegen das immunschwächevirus der Katze
AU6683400A (en) * 1999-07-08 2001-01-30 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
FR2825280B1 (fr) * 2001-06-01 2005-04-15 Merial Sas Vaccination contre le virus de l'immunodeficience feline
EP1673633B9 (de) * 2003-09-11 2011-03-02 Idexx Laboratories, Inc. Verfahren zum nachweis des felinen immunschwächevirus
AU2005267607B8 (en) * 2003-09-11 2009-07-16 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
DE602004021724D1 (de) * 2003-12-18 2009-08-06 Idexx Lab Inc Verfahren zum nachweis des felinen immunschwächevirus
DE602005027326D1 (de) * 2004-02-19 2011-05-19 Idexx Lab Inc Verfahren und vorrichtung zum nachweis von katzen-immunschwächevirus
WO2006011920A1 (en) * 2004-06-30 2006-02-02 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein
US20060003445A1 (en) * 2004-06-30 2006-01-05 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
AU2008314485B9 (en) * 2007-10-15 2015-02-26 Jingang Medicine (Australia) Pty Ltd Expression system for modulating an immune response
US20100291142A1 (en) * 2007-10-18 2010-11-18 Roger Maes Bacterial Artificial Chromosome Containing Feline Herpes Virus Type 1 Genome and Uses Thereof
US8809004B2 (en) 2010-04-02 2014-08-19 Idexx Laboratories, Inc. Detection of feline immunodeficiency virus
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
PT2569436T (pt) 2010-05-14 2018-03-05 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes e seus usos
EP2691530B1 (de) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv-glycoproteine und rekombinante vektoren
AU2014225886B2 (en) 2013-03-05 2020-04-16 Oregon Health & Science University Cytomegalovirus vectors enabling control of T cell targeting
MX2017000658A (es) 2014-07-16 2017-07-07 Univ Oregon Health & Science Citomegalovirus humano compuesto por antígenos exógenos.
WO2016130693A1 (en) 2015-02-10 2016-08-18 Oregon Health & Science University Methods and compositions useful in generating non canonical cd8+ t cell responses
CA3005136A1 (en) 2015-11-20 2017-05-26 Oregon Health & Science University Cmv vectors comprising microrna recognition elements
KR20180083437A (ko) 2015-12-09 2018-07-20 애드메더스 백신스 피티와이 리미티드 치료를 위한 면역조절용 조성물
BR112019007982A2 (pt) 2016-10-18 2019-07-02 Univ Oregon Health & Science vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341439C (en) * 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
US5118602A (en) * 1987-08-26 1992-06-02 The Regents Of The University Of California Feline T-lymphotropic lentivirus assay
US5324664A (en) * 1988-08-08 1994-06-28 The Upjohn Company Herpes virus thymidien kinase-encoding DNA
EP1475442A3 (de) * 1989-05-08 2004-11-17 Idexx Laboratories, Inc. Lymphotropische Polypeptide von dem Lentivirus von den T-zellen der Katze
WO1990015141A2 (en) * 1989-06-01 1990-12-13 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
US6228608B1 (en) 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
CA2122263A1 (en) * 1991-10-28 1993-05-13 Marc Girard Induction of protection against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
ES2188589T3 (es) * 1992-06-26 2003-07-01 Akzo Nobel Nv Vacuna recombinante del herpes virus felino.
GB9215232D0 (en) * 1992-07-17 1992-09-02 Pitman Moore Inc Vaccines
GB9215233D0 (en) * 1992-07-17 1992-09-02 Pitman Moore Inc Vaccines
WO1994003621A1 (en) * 1992-07-30 1994-02-17 Akzo Nobel N.V. Vector vaccines of recombinant feline herpesvirus
AU5138293A (en) * 1992-09-21 1994-04-12 Chiron Viagene, Inc. Recombinant retroviral vector against felv and/or fiv
GB9219936D0 (en) * 1992-09-21 1992-11-04 Pitman Moore Inc Vaccines

Also Published As

Publication number Publication date
EP0758396A1 (de) 1997-02-19
EP0758396B1 (de) 2006-07-26
DE69535125D1 (de) 2006-09-07
AU2234995A (en) 1995-11-29
JPH09512177A (ja) 1997-12-09
DE69535125T2 (de) 2007-08-30
WO1995030019A1 (en) 1995-11-09
ES2267101T3 (es) 2007-03-01
EP1679377A1 (de) 2006-07-12
US5833993A (en) 1998-11-10

Similar Documents

Publication Publication Date Title
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
NZ331161A (en) Synthetic HIV genes encoding envelope (env) proteins
DK0969862T3 (da) Syntetisk HIV gag-gener
FR2741806B1 (fr) Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
EP1847549A3 (de) Polyproteinkonstrukte des Papillomavirus
DE68927025D1 (de) HIV-2-Virusvarianten
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
DK0484382T3 (da) Felint calicivirus-capsid-protein og nucleotidsekvens
ZA941853B (en) Stimulation of immune response by viral protein
AU2003281917A8 (en) Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
AU686000B2 (en) Infectious peritonitis vaccine
Wardley et al. Feline immunodeficiency virus vaccine
DK0732339T3 (da) Peptider fra HIV-gag-proteinet, fremstilling og anvendelse deraf
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
FR2825280B1 (fr) Vaccination contre le virus de l'immunodeficience feline
DE363414T1 (de) Intranasale immunisierung gegen eine virusinfektion unter verwendung eines viralen glykoprotein-impfstoffes.
EA199900726A1 (ru) Синтетические hiv gag гены

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties